Published in Cancer Res on March 15, 1995
Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc Natl Acad Sci U S A (1996) 0.94
Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol (2002) 0.91
Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer (1997) 0.87
Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn (2004) 0.85
Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549. J Exp Clin Cancer Res (2010) 0.83
Inhibition of Breast Tumor Cell Growth by Ectopic Expression of p16/INK4A Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition. J Cancer (2012) 0.83
Expression of p16 gene and Rb protein in gastric carcinoma and their clinicopathological significance. World J Gastroenterol (2005) 0.82
The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells. Korean J Intern Med (1999) 0.77
Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death. Int J Oncol (2007) 0.76
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (1983) 11.57
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A (1999) 7.70
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A (1997) 3.48
Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature (1984) 3.37
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature (1985) 2.96
Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics (1998) 2.79
Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet (1989) 2.56
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Clonal genomic alterations in glioma malignancy stages. Cancer Res (1988) 2.39
Genetic origin of mutations predisposing to retinoblastoma. Science (1985) 2.22
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
A mouse model of orthotopic vascularized aerated lung transplantation. Am J Transplant (2007) 2.16
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature (1987) 2.14
Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A (1989) 2.14
Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1/T1 (CD5). Proc Natl Acad Sci U S A (1987) 2.13
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A (1997) 2.04
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1996) 2.02
Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature (1986) 1.98
Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome (2001) 1.94
Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature (1988) 1.84
Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res (1994) 1.84
Cell-specific transcriptional regulation of follicle-stimulating hormone-beta by activin and gonadotropin-releasing hormone in the LbetaT2 pituitary gonadotrope cell model. Endocrinology (2001) 1.82
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem (1998) 1.79
Genetics of cancer predisposition. Cancer Res (1987) 1.78
Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene (2007) 1.71
D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res (1999) 1.67
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet (1994) 1.66
Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (1998) 1.59
Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci U S A (1996) 1.53
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res (2001) 1.47
Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. Proc Natl Acad Sci U S A (1987) 1.47
Structure of the human retinoblastoma gene. Proc Natl Acad Sci U S A (1989) 1.44
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res (1997) 1.43
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene (2011) 1.42
Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res (1991) 1.42
Human collagen genes encoding basement membrane alpha 1 (IV) and alpha 2 (IV) chains map to the distal long arm of chromosome 13. Proc Natl Acad Sci U S A (1987) 1.41
Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res (1994) 1.39
Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res (1996) 1.38
Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res (1999) 1.37
Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res (2001) 1.34
Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res (1992) 1.31
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
Chromosome 13 homozygosity in osteosarcoma without retinoblastoma. Am J Hum Genet (1986) 1.30
p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res (1994) 1.27
Physical shock wave mediates membrane hyperpolarization and Ras activation for osteogenesis in human bone marrow stromal cells. Biochem Biophys Res Commun (2001) 1.26
Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res (1995) 1.26
Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res (1991) 1.25
Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res (1996) 1.23
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21
Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem (1996) 1.20
Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. DNA (1987) 1.20
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A (1998) 1.19
DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res (1993) 1.18
CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant (2010) 1.17
Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res (1994) 1.17
Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet (1993) 1.13
A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics (1999) 1.12
The p53 gene and its role in human brain tumors. Glia (1995) 1.11
Retinoblastoma and the progression of tumor genetics. Trends Genet (1988) 1.11
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett (2001) 1.11
Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A (2001) 1.11
Advances in the molecular genetics of gliomas. Curr Opin Oncol (1997) 1.10
Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer (1993) 1.10
The potential of TRAIL for cancer chemotherapy. Apoptosis (2001) 1.10
Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2001) 1.10